A shot in the arm for Pharmaniaga


MIDF Research maintained its “buy’’ call with unchanged target price of 98 sen per share.

PETALING JAYA: Pharmaniaga Bhd’s initiative of supplying vaccines out of Malaysia will see its business prospering beyond the local sector.

Its long-term prospects also remains positive and with the group’s other strategies in providing access to its pharmaceuticals as well as increasing capacities and capabilities.

Win a prize this Mother's Day by subscribing to our annual plan now! T&C applies.

Monthly Plan

RM13.90/month

Annual Plan

RM12.33/month

Billed as RM148.00/year

1 month

Free Trial

For new subscribers only


Cancel anytime. No ads. Auto-renewal. Unlimited access to the web and app. Personalised features. Members rewards.
Follow us on our official WhatsApp channel for breaking news alerts and key updates!

Pharmaniaga , Burma , vaccine , export , buy , MIDF research ,

   

Next In Business News

US job growth slows in April; unemployment rate rises to 3.9%
HSBC has no plans to dispose of further businesses, Chairman says
MJets Air inks aircraft charter agreement with Teleport
Ringgit extends gains to end higher against US dollar
S P Setia to launch Nadi 2, Setia Commerce Square in Setia EcoHill 2, Semenyih this weekend
Farm Price IPO oversubscribed by 91.35 times
XOX to undertake RM303mil capital reduction
Uzma bags contract from Sarawak Shell
Loob Holding eyes Tealive chain expansion into Indonesia by year-end
WTK acquires 15% stake in Durafarm for RM28.3mil

Others Also Read